Imaging study for advanced clear cell kidney cancer
Part of Cancer clinical trials.
This early-phase study uses a special imaging agent called RYZ512 to see how it works in people with advanced clear cell kidney cancer that has spread. Participants will receive RYZ512 and have scans; you may qualify if you can pause certain medications temporarily.
Summary written for real people, not researchers, by Clin2.
Who can take part
- At least 18 years old
- Diagnosed with metastatic clear cell renal cell carcinoma (kidney cancer that has spread)
- Not taking certain medications (like seizure or mental health drugs, some pain relievers, or sulfa-based antibiotics) that cannot be stopped for a short time
- Not pregnant or breastfeeding (if you could become pregnant)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at genetic (RNA) testing of kidney cancer tissue to help choose the best drug treatment. It may help guide therapy for people with advanced or metastatic clear cell kidney cancer who are starting treatment for the first time.
This trial tests a new drug called belzutifan combined with a special imaging agent (89Zr-DFO-girentuximab) to see how they affect PET scans in people with advanced clear cell kidney cancer. It may help doctors better understand the cancer and guide treatment.
This study tests a new drug called AK112 (Yiwoxidan Anti) in people with advanced clear cell kidney cancer who cannot take TKI medications. The goal is to see if it is safe and effective.
This trial tests a radioactive treatment (called radiopharmaceutical) that targets a protein called PSMA on kidney cancer cells. It is for people with advanced clear cell kidney cancer that has already been treated with immunotherapy and targeted therapy.
This trial tests a combination of two drugs — an immunotherapy (toripalimab) and a targeted therapy (axitinib) — as the first treatment for advanced kidney cancer. The approach may shrink the tumor before deciding whether and when to remove the kidney surgically.
This trial tests a new radioactive imaging agent (111In-XYIMSR-01) to see how well it finds clear cell kidney cancer that has spread. It involves a special SPECT/CT scan and may help doctors better see where the cancer is.
Hear when a new Metastatic Clear Cell Renal Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.